Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: John S. Baker who wrote (1105)	10/10/1998 12:13:00 PM
From: nord	Read Replies (1) \| Respond to of 1510

an update on Valentines data should be released within the next couple of weeks, If it is as I expect this product alone may well outstrip agph viracept, to date the largest single product launch first year revenue ever for a biotech, ie that includes amgen. As a physician of infectious disease if this drug in fact promotes durability of the antiviral regimen we already have then we may be well on our way to having a powerful long term treatment for the suppression of HIV replication and hence its clinical manifestations. The news will present some durability data ie how effective and for how long does the drug work. Lets all pray for the people with this infection and hope that Salk's name and ideas and dreams for humanity live on in this company for which he saw so much potential for improving the lives of the ill. Regards Norden